<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:doc-QQXI28HL</identifier><date>2023</date><creator>Janić, Miodrag</creator><creator>Lunder, Mojca</creator><creator>Pučnik, Tina</creator><relation>documents/doc/Q/URN_NBN_SI_doc-QQXI28HL_001.pdf</relation><relation>documents/doc/Q/URN_NBN_SI_doc-QQXI28HL_001.txt</relation><format format_type="issue">3/4</format><format format_type="volume">93</format><format format_type="type">article</format><format format_type="extent">str. 146</format><identifier identifier_type="DOI">10.6016/ZdravVestn.3514</identifier><identifier identifier_type="ISSN">1318-0347</identifier><identifier identifier_type="COBISSID_HOST">209326851</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-QQXI28HL</identifier><language>slv</language><publisher publisher_location="Ljubljana">Slovensko zdravniško društvo</publisher><source>Zdravniški vestnik</source><rights>BY-NC</rights><subject language_type_id="eng">dapagliflozin</subject><subject language_type_id="eng">diabetic ketoacidosis</subject><subject language_type_id="eng">empagliflozin</subject><subject language_type_id="eng">risk factors</subject><subject language_type_id="eng">SGLT-2 inhibitors</subject><title>Dodatek k prispevku</title><title>Diabetična ketoacidoza</title><title>redek, a resen zaplet zdravljenja z zaviralci SGLT-2 – pregled literature in prikaz serije primerov</title></Record>